USPTO serial 79282685
CANOPY Y IMMUNO-THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 12, 2021
- Examiner
- CAYSIDO, REBECCA TOLENTINO
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CANOPY Y IMMUNO-THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
ROY D GROSS
ROY D GROSS THE ROY GROSS LAW FIRM LLC50 WASHINGTON STREET, SUITE 737/745NORWALK, CT 06854UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials for the treatment of autoimmune diseases, by eliminating specific lymphocytes' lineages or modulating the immune response using a variety of organic compounds and recombinant proteins; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials that modulate the immune system by recombinant proteins that contain a targeting moiety and an effect or moiety to eliminate specific lymphocytes' lineages and attenuate or block antibody creation and antigen-specific immune response in autoimmune diseases for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant proteins and substances not related to pharmaceuticals and clinical trials that modulate the immune system by recombinant proteins that contain a targeting moiety and an effect or moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen-specific immune response in autoimmune diseases for the treatment of autoimmune diseases and disorders; Pharmaceutical recombinant protein preparations and substances not related to pharmaceuticals and clinical trials with potential immunomodulation activity to treat under and over responsiveness of the immune system for the treatment of autoimmune diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CANOPY IMMUNO-THERAPEUTICS LTD.
- Other trademarks owned by CANOPY IMMUNO-THERAPEUTICS LTD.
- Other trademarks owned by CANOPY IMMUNO-THERAPEUTICS LTD.
- Other trademarks in Class 005
- Similar marks named CANOPY Y IMMUNO-THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 12, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 10, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 19, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 18, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 12, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 12, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 3, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 15, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 15, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 27, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 27, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 24, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 7, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 7, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 7, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 24, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 24, 2021 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 24, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 25, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 25, 2021 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| May 25, 2021 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 25, 2021 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| May 24, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 24, 2021 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 24, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 12, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 25, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 25, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 25, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 4, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 4, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 4, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 28, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 12, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 28, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 28, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 8, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 7, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 14, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 10, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 9, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |